Main > ONCOLOGY (**) > Breast Cancer>HER2+ *** > Prognostics > ES. R. Recurrence/Therapy Response>

---

ES. R. Recurrence/Therapy Response>'s subsections
(*) Market Date: 2022. 02.17.
>Genomic Test
Company
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 3
Patent>UpDate: 2022. 02.15
RTM
RTM Web-Site

ES. R. Recurrence/Therapy Response>'s products
This section has no products